NCT06977737

A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours

A Phase 1-2 Master Protocol to Study Intravenous ATTR-01 in Adult Participants With Select Epithelial Solid Tumours Under Multiple Sub-protocols

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Accession Therapeutics Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells. This virus delivers an immune therapy drug into the cancer that is intended to promote a participant's own immune system to attack the cancer. The first part of this trial (sub-protocol A) is a phase 1 trial including dose escalation and expansion at one or more doses. It is the first time that ATTR-01 will be given to humans. If an optimal dose is identified, additional sub-protocols will be added by to further elicit whether ATTR-01 may successfully treat cancer. Expanded access is not available.

Conditions

• Solid Tumor, Adult

Interventions

Type	Name	Description
DRUG	ATTR-01	Intravenous injection

Timeline

• Start date: 2025-03-21
• Primary completion: 2029-12-31
• Completion: 2034-12-31
• First posted: 2025-05-18
• Last updated: 2026-03-25

Locations

7 sites across 2 countries: Spain, United Kingdom